All In Biotech

Drug Trial Radar · NCT03866382

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

314

Planned (sponsor's estimate)

Start

May 13, 2019

Primary completion

Feb 28, 2027

Study completion Feb 28, 2027

Sponsor

Sponsor type
NIH
First posted
Mar 7, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.

Conditions

  • Bladder Adenocarcinoma
  • Bladder Clear Cell Adenocarcinoma
  • Bladder Mixed Adenocarcinoma
  • Bladder Neuroendocrine Carcinoma
  • Bladder Small Cell Neuroendocrine Carcinoma
  • Bladder Squamous Cell Carcinoma
  • Chromophobe Renal Cell Carcinoma
  • Collecting Duct Carcinoma
  • Invasive Bladder Giant Cell Urothelial Carcinoma
  • Invasive Bladder Lymphoepithelioma-Like Carcinoma
  • Invasive Bladder Nested Urothelial Carcinoma
  • Invasive Bladder Plasmacytoid Urothelial Carcinoma
  • Invasive Bladder Sarcomatoid Urothelial Carcinoma
  • Invasive Bladder Urothelial Carcinoma
  • Kidney Medullary Carcinoma
  • Large Cell Neuroendocrine Carcinoma
  • Malignant Testicular Leydig Cell Tumor
  • Malignant Testicular Sertoli Cell Tumor
  • Metastatic Bladder Carcinoma
  • Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma
  • Metastatic Bladder Giant Cell Urothelial Carcinoma
  • Metastatic Bladder Large Cell Neuroendocrine Carcinoma
  • Metastatic Bladder Lipid-Rich Urothelial Carcinoma
  • Metastatic Bladder Micropapillary Urothelial Carcinoma
  • Metastatic Bladder Plasmacytoid Urothelial Carcinoma
  • Metastatic Bladder Sarcomatoid Urothelial Carcinoma
  • Metastatic Bladder Small Cell Neuroendocrine Carcinoma
  • Metastatic Bladder Squamous Cell Carcinoma
  • Metastatic Chromophobe Renal Cell Carcinoma
  • Metastatic Kidney Medullary Carcinoma
  • Metastatic Malignant Genitourinary System Neoplasm
  • Metastatic Papillary Renal Cell Carcinoma
  • Metastatic Penile Carcinoma
  • Metastatic Prostate Small Cell Neuroendocrine Carcinoma
  • Metastatic Sarcomatoid Renal Cell Carcinoma
  • Metastatic Urethral Carcinoma
  • Papillary Renal Cell Carcinoma
  • Sarcomatoid Renal Cell Carcinoma
  • Stage IV Bladder Cancer AJCC v8
  • Stage IV Penile Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8
  • Stage IV Urethral Cancer AJCC v8
  • Stage IVB Prostate Cancer AJCC v8
  • Urachal Adenocarcinoma
  • Urethral Clear Cell Adenocarcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood and urine sample collection

  • Bone ScanProcedure

    Undergo bone scan

  • Cabozantinib S-malateDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT and/or PET/CT scan

  • Echocardiography TestProcedure

    Undergo echocardiography

  • IpilimumabBiological

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • NivolumabBiological

    Given IV

  • Positron Emission TomographyProcedure

    Undergo PET/CT scan

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Up to 5 years

Locations

582 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska · Suspended

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska · Suspended

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska · Suspended

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska · Suspended

  • Alaska Women's Cancer Care

    Anchorage, Alaska · Suspended

  • Anchorage Oncology Centre

    Anchorage, Alaska · Suspended

  • Katmai Oncology Group

    Anchorage, Alaska · Suspended

  • Providence Alaska Medical Center

    Anchorage, Alaska · Suspended

  • Kingman Regional Medical Center

    Kingman, Arizona · Suspended

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona · Active not recruiting

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona · Recruiting

  • Mayo Clinic in Arizona

    Scottsdale, Arizona · Recruiting

  • University of Arizona Cancer Center-Orange Grove Campus

    Tucson, Arizona · Active not recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Active not recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Active not recruiting

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas · Suspended

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas · Suspended

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California · Active not recruiting

  • PCR Oncology

    Arroyo Grande, California · Suspended

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California · Suspended

  • Community Cancer Institute

    Clovis, California · Active not recruiting

  • University Oncology Associates

    Clovis, California · Active not recruiting

  • Epic Care-Dublin

    Dublin, California · Active not recruiting

  • Bay Area Breast Surgeons Inc

    Emeryville, California · Active not recruiting

  • Epic Care Partners in Cancer Care

    Emeryville, California · Active not recruiting

  • Marin Cancer Care Inc

    Greenbrae, California · Suspended

  • Keck Medicine of USC Koreatown

    Los Angeles, California · Recruiting

  • Los Angeles General Medical Center

    Los Angeles, California · Recruiting

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California · Recruiting

  • UCLA / Jonsson Comprehensive Cancer Center

    Los Angeles, California · Completed

  • Contra Costa Regional Medical Center

    Martinez, California · Active not recruiting

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California · Recruiting

  • Alta Bates Summit Medical Center - Summit Campus

    Oakland, California · Suspended

  • Bay Area Tumor Institute

    Oakland, California · Active not recruiting

  • Pacific Central Coast Health Center-San Luis Obispo

    San Luis Obispo, California · Active not recruiting

  • Mission Hope Medical Oncology - Santa Maria

    Santa Maria, California · Active not recruiting

  • Epic Care Cyberknife Center

    Walnut Creek, California · Active not recruiting

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado · Active not recruiting

  • Rocky Mountain Cancer Centers-Penrose

    Colorado Springs, Colorado · Active not recruiting

Showing 40 of 582 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.